Oncotype DX maker Genomic Health announced last week that two studies recently presented at an international oncology conference could lead to the development of new predictive tests to help determine which patients are likely to respond to the targeted colon cancer drug Erbitux and the breast cancer chemotherapy Taxotere.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.